ABG Analyst expects significant costs increase at Coloplast
ABG Sundal Collier has lowered its recommendation for Coloplast from "hold" to "sell" as it anticipates that the medtech company's costs will increase considerably in the future.
BY MARKETWIRE OG CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN
Coloplast has had its recommendation lowered to "sell" from "hold" by the investment bank ABG Sundal Collier.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Coloplast recalls urology products
For subscribers
